At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 592 enrolled
Drug / intervention
DE-109 44 ug +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III, Multinational, Multicenter, Randomized, Double-Masked, Study for the Treatment of Active, Non-Infectious Uveitis of the Posterior Segment of the Eye
In Brief
A Phase 3 clinical trial evaluating DE-109 44 ug, DE-109 440 ug, and 1 other intervention for Uveitis; Posterior, Disorder. Completed, enrolled 592 participants across 151 sites in 17 countries.
Detailed Summary
The purpose of this study is to evaluate the safety and efficacy of intravitreal injections of DE-109 ophthalmic solution.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUveitis; Posterior, Disorder
CountriesArgentina, Austria, Brazil, Chile, Colombia, France, Germany, India, Israel, Italy, Japan, Peru, Poland, Spain, Turkey (Türkiye), United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMay 2011
First PostedMay 2011
Primary CompletionSep 2016
Study CompletionDec 2016
TodayJul 2026
First PostedMay 23, 2011
Enrollment StartMay 1, 2011
Primary CompletionSep 1, 2016
Study CompletionDec 1, 2016
TodayJul 2, 2026
Enrollment to primary: 5.3 yearsPosted 15.1 years ago
Interventions
DE-109 44 ugdrug
Low dose
DE-109 440 ugdrug
Medium dose
DE-109 880 ugdrug
High dose